Immune Checkpoint Inhibitor-associated Myositis in a Patient with Metastatic Cholangiocarcinoma
10.46518/kjnmd.2024.16.2.43
- Author:
Chung Seok LEE
1
;
Soo-Hyun KIM
;
Sung Rok LEE
;
Young-Chul CHOI
;
Hyung Jun PARK
Author Information
1. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Publication Type:Case Report
- From:
Korean Journal of Neuromuscular Disorders
2024;16(2):43-46
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
An 83-year-old man with cholangiocarcinoma developed immune checkpoint inhibitor-associated myositis after two cycles of durvalumab, presenting with muscle weakness and myalgia. His serum creatine kinase (CK) level peaked at 26,329 U/L. Needle electromyography confirmed a myogenic process, and MRI revealed extensive muscle edema. Muscle biopsy indicated multifocal necrotic fibers. Following steroid treatment, his CK levels normalized and muscle strength returned. This case represents the first reported instance of durvalumab-associated myositis in Korea.
